Every Form 4 that Prelude Therapeutics Incorporated (PRLD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PRLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRLD filings page.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Prelude Therapeutics Inc reported a routine compensation grant involving its board representative from Baker Bros. Advisors. Dr. Paul C. Scherer, who serves on the board, received a grant of 38,000 non-qualified stock options exercisable into common stock at a strike price of $3.94 per share. The options vest on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual stockholder meeting, and expire on June 8, 2036. The filing explains that, under Baker Bros. Advisors’ policies, Dr. Scherer has no personal right to these securities; instead, affiliated funds, including 667, L.P. and Baker Brothers Life Sciences LP, hold an indirect proportionate pecuniary interest, while Baker Bros. Advisors retains voting and dispositive power. Julian and Felix Baker may be deemed to have only an indirect pecuniary interest through their ownership interests in the related entities and expressly disclaim broader beneficial ownership.
Prelude Therapeutics Inc reported that director Katina Dorton received a grant of stock options covering 38,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036.
The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Dorton continues providing service to the company through the vesting date. Following this grant, she holds options for 38,000 shares directly.
Prelude Therapeutics Inc director Martin Babler received a grant of options to buy 38,000 shares of common stock as compensation. The options have an exercise price of $3.94 per share and expire on June 8, 2036.
The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, subject to his continued service. Following this grant, Babler directly holds options for 38,000 underlying common shares.
Prelude Therapeutics Inc director David P. Bonita received a grant of stock options covering 38,000 shares of Common Stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036. The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, subject to continued service. Under an agreement, any securities or economic benefit from these options are required to be transferred to OrbiMed-related entities.
Prelude Therapeutics Inc director Sandor Victor received a grant of stock options covering 38,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036.
The award will fully vest upon the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Victor continues providing service through the applicable vesting date. After this grant, he holds options for 38,000 shares directly.
Prelude Therapeutics Inc director Paul A. Friedman received a grant of stock options as part of his board compensation. The award covers 38,000 options to buy common stock at an exercise price of $3.94 per share and expires on June 8, 2036. The options will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, provided he continues serving the company through the vesting date.
Prelude Therapeutics Inc reported that Chief Medical Officer Charles Q. Morris received an employee stock option grant covering 450,000 shares of common stock at an exercise price of $4.70 per share.
The option vests 25% on May 1, 2027, then 1/48 of the total shares monthly until fully vested, contingent on continued service. The option expires on April 30, 2036, and all 450,000 options are reported as held directly following this grant.
Prelude Therapeutics Inc disclosed that RA Capital Healthcare Fund, L.P., an entity associated with RA Capital Management, entered into an Exchange Agreement with the company. The Fund exchanged 1,407,000 shares of Common Stock for a Pre-Funded Warrant exercisable for up to 1,407,000 Common shares at an exercise price of $0.0001 per share, for no additional consideration.
The Pre-Funded Warrant is exercisable immediately, has no expiration date, and includes a 9.99% beneficial ownership cap that limits exercises if they would push the Fund and its attribution parties above that ownership level. Following the restructuring, the Fund indirectly held 6,475,882 shares of Common Stock and 1,407,000 Pre-Funded Warrants. RA Capital Management, its general partner, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership except to the extent of their respective pecuniary interests.
Prelude Therapeutics Inc reported that investment entities affiliated with OrbiMed made indirect open-market purchases of its Common Stock in connection with an underwritten public offering. OrbiMed-related funds acquired blocks of 1,126,126 and 1,689,189 shares at $4.44 per share, with indirect holdings after one transaction reaching 11,808,945 shares. The securities are held of record by OrbiMed-managed funds, and OrbiMed Advisors exercises voting and investment power through a management committee. David P. Bonita, a director and ten percent owner, reports these positions but, together with the OrbiMed entities, disclaims beneficial ownership except to the extent of any pecuniary interest.
Prelude Therapeutics Inc reported that investment entities affiliated with OrbiMed made significant open-market purchases of its common stock. OrbiMed-related funds bought a combined 2,815,315 shares at $4.44 per share in an underwritten public offering, with all holdings reported as indirect and subject to detailed ownership footnotes.
The filing attributes shares to OrbiMed Private Investments VI, OrbiMed Partners Master Fund, and OrbiMed Genesis Master Fund through their respective general partners and advisors, while OrbiMed reporting entities and individual managers disclaim beneficial ownership beyond any pecuniary interest. One OrbiMed representative, David Bonita, serves on Prelude’s board.
Prelude Therapeutics Inc reported that investment funds advised by Baker Bros. Advisors LP made open-market purchases of prefunded warrants in an underwritten public offering. 667, L.P. acquired 114,601 prefunded warrants and Baker Brothers Life Sciences LP acquired 2,137,651 prefunded warrants, each at $4.4399 per warrant.
The prefunded warrants are exercisable into common stock on a 1-for-1 basis at an exercise price of $0.0001 per share, with no expiration date. Exercises are limited so that the holders and certain affiliates do not exceed 4.99% beneficial ownership, a cap the funds can adjust up to 19.99% with advance written notice. Baker Bros. Advisors LP has investment and voting discretion over the funds’ positions, while various Baker entities and Julian and Felix Baker disclaim beneficial ownership beyond their pecuniary interests.
Prelude Therapeutics reported a stock option grant to Chief Chemistry Officer Andrew Combs. On February 4, 2026, he received an employee stock option covering 230,000 shares of common stock at an exercise price of $2.30 per share.
The option vests over four years: 25% of the shares vest on February 4, 2027, and the remaining 75% vest in equal monthly installments (1/48 of the total shares) until fully vested, as long as Combs continues providing service to the company on each vesting date.
Prelude Therapeutics reported that Chief Scientific Officer Peggy Scherle received an employee stock option grant on February 4, 2026. The derivative award covers 230,000 shares of common stock at an exercise price of $2.30 per share, with no cash paid for the option itself.
The option vests over time: 25% of the total shares vest on February 4, 2027, and the remaining shares vest in equal monthly installments of 1/48 of the total until fully vested. Following this grant, Scherle beneficially holds 230,000 stock options, all reported as directly owned.
Prelude Therapeutics granted its CLO, CFO and Corporate Secretary Bryant D. Lim an employee stock option covering 275,000 shares of common stock on February 4, 2026. The option has an exercise price of $2.30 per share and is held as a direct ownership position.
The award vests over four years: 25% of the shares vest on February 4, 2027, and the remaining 75% vest in equal monthly installments of 1/48 of the total grant until fully vested, conditioned on Mr. Lim continuing to provide services to the company on each vesting date.
Prelude Therapeutics CEO Krishna Vaddi received a large stock option grant. The Form 4 reports an employee stock option to purchase 837,000 shares of Prelude Therapeutics common stock at an exercise price of $2.30 per share, granted on February 4, 2026.
The option expires on February 3, 2036. It vests 25% on February 4, 2027, then 1/48 of the total shares vests monthly until fully vested, as long as Vaddi continues providing services to the company on each vesting date.
Prelude Therapeutics (PRLD) reported a director equity grant. On 11/05/2025, the reporting person received stock options for 121,285 shares at an exercise price of $1.39 per share. The options vest over one year, at one‑twelfth each month, and expire on 11/04/2035. The filing was made by one reporting person with direct ownership.
Prelude Therapeutics (PRLD) reported an insider equity grant on a Form 4. On 10/17/2025, a director received 76,000 director stock options at an exercise price of $1.19 per share, expiring on 10/16/2035.
The award vests over three years at one‑thirty‑sixth per month, subject to continued service. Following the transaction, the reporting person beneficially owned 76,000 derivative securities, held directly.
Jane Huang, President and CMO of Prelude Therapeutics Inc (PRLD), reported transactions on 10/04/2025 showing the vesting and withholding related to restricted stock units (RSUs). 9,375 RSUs became vested (transaction code M), creating a contingent right to the same number of common shares; those RSUs increased her direct ownership before withholding to 90,272 shares. The company withheld 3,355 shares to satisfy tax obligations at a withholding price of $1.47, leaving 86,917 shares beneficially owned after the taxable disposition. The filing notes the RSUs were granted on 05/02/2022 and follow a vesting schedule that began with 1/4 vesting on 04/04/2023 and quarterly vesting of the remainder while employment continues. The report is signed by an attorney-in-fact on 10/07/2025.